Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The role of the Notch signaling pathway in tumor development is complex, with Notch1 functioning either as an oncogene or as a tumor suppressor in a context-dependent manner. To further define the role of Notch1 in tumor development, we systematically surveyed for tumor suppressor activity of Notch1 in vivo. We combined the previously described Notch1 intramembrane proteolysis-Cre (Nip1::Cre) allele with a floxed Notch1 allele to create a mouse model for sporadic, low-frequency loss of Notch1 heterozygosity. Through this approach, we determined the cell types most affected by Notch1 loss. We report that the loss of Notch1 caused widespread vascular tumors and organism lethality secondary to massive hemorrhage. These findings reflected a cell-autonomous role for Notch1 in suppressing neoplasia in the vascular system and provide a model by which to explore the mechanism of neoplastic transformation of endothelial cells. Importantly, these results raise concerns regarding the safety of chronic application of drugs targeting the Notch pathway, specifically those targeting Notch1, because of mechanism-based toxicity in the endothelium. Our strategy also can be broadly applied to induce sporadic in vivo loss of heterozygosity of any conditional alleles in progenitors that experience Notch1 activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, a chronic blockade of Notch signaling leads to vascular tumors of the liver, skin, ovary, testes and colon in mice [140, 141].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [140]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Generalized lacZ expression with the ROSA26 Cre reporter strain
Soriano, P. (1999) · Nature Genetics · doi:10.1038/5007 · Cited by 4,859 · cited 6×
“We have previously reported that when N1::Cre is combined with the RosaLacZ reporter, the excision of the floxed stop cassette by ligand-dependent release of Cre indelibly labels cells that have experienced Notch1 activation.”
BackgroundInfluentialThe Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism
Kopan, R., & Ilagan, M. X. G. (2009) · Cell · doi:10.1016/j.cell.2009.03.045 · Cited by 3,643 · cited 1×
“Introduction The Notch pathway is an evolutionarily conserved signaling mechanism that plays essential roles both during development and in the maintenance of adult tissue homeostasis in metazoan (1).”
BackgroundSelf-citationCre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus
Srinivas, S., Watanabe, T., Lin, C.-S., William, C. M., Tanabe, Y., Jessell, T. M., & Costantini, F. (2001) · BMC Developmental Biology · doi:10.1186/1471-213x-1-4 · Cited by 3,121 · cited 8×
“CD105+CD45– proliferating liver ECs from N1::Crelo/flRosaEYFP/LacZ and N1::Crelo/+RosaEYFP/LacZ mice were collected (Figure 6A), and the DNA was purified and subjected to PCR amplification in order to detect the 3 Notch1 alleles: a normal promoter in the N1::Crelo allele, a floxed promoter in N1fl allele, and a rearra…”
BackgroundInfluentialActivating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,715 · cited 2×
“Jeannet R, et al. Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL [published online ahead of print September 9, 2010].”
Backgroundvan Es, J. H., van Gijn, M. E., Riccio, O., van den Born, M., Vooijs, M., Begthel, H., Cozijnsen, M., Robine, S., Winton, D. J., Radtke, F., et al. (2005) · Nature · doi:10.1038/nature03659 · Cited by 1,543 · cited 1×
“Considering that Notch1 is continuously required in multiple tissues during development and in the adult (33), especially in the gut (7, 34) and mammary gland (35) stem cell populations, a NIP::Cre allele coupled with floxed alleles of tumor suppressors offers a better model to mimic LOH disease development in human p…”
BackgroundNotch signaling is essential for vascular morphogenesis in mice
Krebs, L. T., Xue, Y., Norton, C. R., Shutter, J. R., Maguire, M., Sundberg, J. P., Gallahan, D., Closson, V., Kitajewski, J., Callahan, R., et al. (2000) · Genes & Development · doi:10.1101/gad.14.11.1343 · Cited by 1,060 · cited 1×
“Concomitant loss of signals from other Notch receptors, such as Notch4 in ECs (38) and Notch2/3 in pericytes (39–41), may have accelerated the tumor formation in their model (37).”
BackgroundBlockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Noguera-Troise, I., Daly, C., Papadopoulos, N. J., Coetzee, S., Boland, P., Gale, N. W., Chieh Lin, H., Yancopoulos, G. D., & Thurston, G. (2006) · Nature · doi:10.1038/nature05355 · Cited by 1,032 · cited 4×
“The Notch pathway has emerged as a target to block angiogenesis in solid tumors (9, 10, 36) and eliminate tumor-initiating cells (13), either by the administration of anti-Dll4 antibody Figure 5 Characterization of vascular tumor cells.”
BackgroundResultInfluentialInhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.-C., Chanthery, Y., Kowalski, J., Watts, R. J., Callahan, C., Kasman, I., et al. (2006) · Nature · doi:10.1038/nature05313 · Cited by 986 · cited 4×
“The Notch pathway has emerged as a target to block angiogenesis in solid tumors (9, 10, 36) and eliminate tumor-initiating cells (13), either by the administration of anti-Dll4 antibody Figure 5 Characterization of vascular tumor cells.”
BackgroundResultInfluentialNotch1 functions as a tumor suppressor in mouse skin
Nicolas, M., Wolfer, A., Raj, K., Kummer, J. A., Mill, P., van Noort, M., Hui, C.-C., Clevers, H., Dotto, G. P., & Radtke, F. (2003) · Nature Genetics · doi:10.1038/ng1099 · Cited by 971 · cited 1×
“In contrast to gain-offunction mutations in Notch1 and their oncogenic role in T-ALL (3, 4), and perhaps in solid tumors, Notch1 loss-of-function mutations have only been implicated in a limited number of tumors, such as skin (2), where Notch1 loss promotes tumor formation non–cell-autonomously by creating a wound-lik…”
BackgroundNotch1 is required for the coordinate segmentation of somites
Conlon, R. A., Reaume, A. G., & Rossant, J. (1995) · Development · doi:10.1242/dev.121.5.1533 · Cited by 852
Endothelial cell diversity revealed by global expression profiling
Chi, J.-T., Chang, H. Y., Haraldsen, G., Jahnsen, F. L., Troyanskaya, O. G., Chang, D. S., Wang, Z., Rockson, S. G., van de Rijn, M., Botstein, D., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1434429100 · Cited by 771 · cited 1×
“Alternatively, some unique features of liver ECs (32), as well as the specific anatomical or environmental factor(s), may predispose the liver to vascular tumor formation.”
BackgroundDirect inhibition of the NOTCH transcription factor complex
Moellering, R. E., Cornejo, M., Davis, T. N., Bianco, C. D., Aster, J. C., Blacklow, S. C., Kung, A. L., Gilliland, D. G., Verdine, G. L., & Bradner, J. E. (2009) · Nature · doi:10.1038/nature08543 · Cited by 752 · cited 1×
“9), anti-Dll4 antibodies (9, 10, 13), dominant-negative Mastermindlike 1 (MAML1) mimetics (14), or γ-secretase inhibitors, which are being considered as therapeutic interventions for cancer.”
BackgroundNotch1 is essential for postimplantation development in mice.
Swiatek, P. J., Lindsell, C. E., del Amo, F. F., Weinmaster, G., & Gridley, T. (1994) · Genes & Development · doi:10.1101/gad.8.6.707 · Cited by 734 · cited 1×
“The embryonic lethality associated with loss of Notch1 (28, 29) prevents a comprehensive evaluation of its role in various organs in later embryonic stages or in the adult.”
BackgroundTherapeutic antibody targeting of individual Notch receptors
Wu, Y., Cain-Hom, C., Choy, L., Hagenbeek, T. J., de Leon, G. P., Chen, Y., Finkle, D., Venook, R., Wu, X., Ridgway, J., et al. (2010) · Nature · doi:10.1038/nature08878 · Cited by 720 · cited 2×
“Notch therapies in general, and anti-Notch1 therapies in particular (11), needs to be carefully reevaluated.”
BackgroundGrowth inhibition and DNA damage induced by Cre recombinase in mammalian cells
Loonstra, A., Vooijs, M., Beverloo, H. B., Allak, B. A., van Drunen, E., Kanaar, R., Berns, A., & Jonkers, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161269798 · Cited by 590 · cited 1×
“To control for the possible contribution from the Cre protein (17) or from Notch1 heterozygosity (18, 19), we compared mutant N1::Crelo/fl mice with control N1::Crelo/+ littermates throughout this study.”
MethodNotch3 is required for arterial identity and maturation of vascular smooth muscle cells
Domenga, V., Fardoux, P., Lacombe, P., Monet, M., Maciazek, J., Krebs, L. T., Klonjkowski, B., Berrou, E., Mericskay, M., Li, Z., et al. (2004) · Genes & Development · doi:10.1101/gad.308904 · Cited by 536
Notch Signaling Regulates Mammary Stem Cell Function and Luminal Cell-Fate Commitment
Bouras, T., Pal, B., Vaillant, F., Harburg, G., Asselin-Labat, M.-L., Oakes, S. R., Lindeman, G. J., & Visvader, J. E. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.08.001 · Cited by 443 · cited 1×
“Considering that Notch1 is continuously required in multiple tissues during development and in the adult (33), especially in the gut (7, 34) and mammary gland (35) stem cell populations, a NIP::Cre allele coupled with floxed alleles of tumor suppressors offers a better model to mimic LOH disease development in human p…”
BackgroundRiccio, O., van Gijn, M. E., Bezdek, A. C., Pellegrinet, L., van Es, J. H., Zimber‐Strobl, U., Strobl, L. J., Honjo, T., Clevers, H., & Radtke, F. (2008) · EMBO reports · doi:10.1038/embor.2008.7 · Cited by 410
DLL4 Blockade Inhibits Tumor Growth and Reduces Tumor-Initiating Cell Frequency
Hoey, T., Yen, W.-C., Axelrod, F., Basi, J., Donigian, L., Dylla, S., Fitch-Bruhns, M., Lazetic, S., Park, I.-K., Sato, A., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.05.019 · Cited by 398 · cited 3×
“The Notch pathway has emerged as a target to block angiogenesis in solid tumors (9, 10, 36) and eliminate tumor-initiating cells (13), either by the administration of anti-Dll4 antibody Figure 5 Characterization of vascular tumor cells.”
BackgroundNotch and cancer: a double-edged sword
Koch, U., & Radtke, F. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7164-1 · Cited by 333 · cited 2×
“Consequently, Notch1 can act either as a tumor suppresser or as an oncogene (2).”
BackgroundThe Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth
Thurston, G., Noguera-Troise, I., & Yancopoulos, G. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2130 · Cited by 290 · cited 1×
“The Notch pathway has emerged as a target to block angiogenesis in solid tumors (9, 10, 36) and eliminate tumor-initiating cells (13), either by the administration of anti-Dll4 antibody Figure 5 Characterization of vascular tumor cells.”
BackgroundChronic DLL4 blockade induces vascular neoplasms
Yan, M., Callahan, C. A., Beyer, J. C., Allamneni, K. P., Zhang, G., Ridgway, J. B., Niessen, K., & Plowman, G. D. (2010) · Nature · doi:10.1038/nature08751 · Cited by 280 · cited 2×
“Consistent with our observation, Yan and colleagues recently showed that chronic injection of Dll4 antibodies into adult mice, rats, and monkeys induces vascular neoplasm only in rats (37).”
BackgroundEpidermal Notch1 Loss Promotes Skin Tumorigenesis by Impacting the Stromal Microenvironment
Demehri, S., Turkoz, A., & Kopan, R. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.05.016 · Cited by 265 · cited 2×
“Unlike the skin, in which tumor promotion is elicited by the non–cell-autonomous consequences of a woundlike environment (5), the tumor suppressor function of Notch1 ECs appears to be cell autonomous.”
BackgroundSelf-citationMorimoto, M., Liu, Z., Cheng, H.-T., Winters, N., Bader, D., & Kopan, R. (2010) · Journal of Cell Science · doi:10.1242/jcs.058669 · Cited by 235 · cited 1×
“amount of N1::Cre fusion protein, is described previously (21, 20) and”
Self-citationSainson, R. C. A., Aoto, J., Nakatsu, M. N., Holderfield, M., Conn, E., Koller, E., & Hughes, C. C. W. (2005) · The FASEB Journal · doi:10.1096/fj.04-3172fje · Cited by 227 · cited 1×
“The presence of a functional Notch1 in pan-ECs but not CD105+ proliferating ECs, the exclusive BrdU labeling of EYFP+ ECs (but not any other linage in the liver; Figure 5A), and the presence of hyperphosphorylated retinoblastoma protein (Rb; Figure 5, B–E) strongly argue that Notch1 suppresses proliferation and vascul…”
BackgroundNoseda, M., Chang, L., McLean, G., Grim, J. E., Clurman, B. E., Smith, L. L., & Karsan, A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.20.8813-8822.2004 · Cited by 218 · cited 1×
“The presence of a functional Notch1 in pan-ECs but not CD105+ proliferating ECs, the exclusive BrdU labeling of EYFP+ ECs (but not any other linage in the liver; Figure 5A), and the presence of hyperphosphorylated retinoblastoma protein (Rb; Figure 5, B–E) strongly argue that Notch1 suppresses proliferation and vascul…”
BackgroundLearning and Memory Deficits in Notch Mutant Mice
Costa, R. M., Honjo, T., & Silva, A. J. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00492-5 · Cited by 207 · cited 1×
“To control for the possible contribution from the Cre protein (17) or from Notch1 heterozygosity (18, 19), we compared mutant N1::Crelo/fl mice with control N1::Crelo/+ littermates throughout this study.”
MethodAste-Amézaga, M., Zhang, N., Lineberger, J. E., Arnold, B. A., Toner, T. J., Gu, M., Huang, L., Vitelli, S., Vo, K. T., Haytko, P., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009094 · Cited by 178 · cited 1×
“This finding raises concerns about Notch-targeting therapies in humans, in which vascular tumors may arise after chronic exposure to inhibitory Notch1 antibodies (11, 12), decoy ligands (such as Dll4; ref.”
BackgroundIsolation of endothelial cells from fresh tissues
van Beijnum, J. R., Rousch, M., Castermans, K., van der Linden, E., & Griffioen, A. W. (2008) · Nature Protocols · doi:10.1038/nprot.2008.71 · Cited by 175
Demehri, S., Liu, Z., Lee, J., Lin, M.-H., Crosby, S. D., Roberts, C. J., Grigsby, P. W., Miner, J. H., Farr, A. G., & Kopan, R. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060123 · Cited by 174
Self-citationReal-time imaging of ligand-induced IKK activation in intact cells and in living mice
Gross, S., & Piwnica-Worms, D. R. (2005) · Nature Methods · doi:10.1038/nmeth779 · Cited by 153
Self-citationMapping the consequence of Notch1 proteolysis in vivo with NIP-CRE
Vooijs, M., Ong, C.-T., Hadland, B., Huppert, S., Liu, Z., Korving, J., van den Born, M., Stappenbeck, T., Wu, Y., Clevers, H., et al. (2007) · Development · doi:10.1242/dev.02733 · Cited by 146 · cited 4×
“This unique activation mechanism allowed us to generate N1::Cre knockin mice (7), in which exons 28–31 of a Notch1 allele (N1) are replaced with cDNA encoding the λ-phage–derived site-specific recombinase Cre and a C-terminal 6Xmyc tag (6MT).”
BackgroundInfluentialSelf-citationGivogri, M. I., de Planell, M., Galbiati, F., Superchi, D., Gritti, A., Vescovi, A., de Vellis, J., & Bongarzone, E. R. (2006) · Developmental Neuroscience · doi:10.1159/000090755 · Cited by 145 · cited 1×
“To control for the possible contribution from the Cre protein (17) or from Notch1 heterozygosity (18, 19), we compared mutant N1::Crelo/fl mice with control N1::Crelo/+ littermates throughout this study.”
MethodCampos, A. H., Wang, W., Pollman, M. J., & Gibbons, G. H. (2002) · Circulation Research · doi:10.1161/01.res.0000044944.99984.25 · Cited by 144
Vauclair, S., Majo, F., Durham, A., Ghyselinck, N. B., Barrandon, Y., & Radtke, F. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.06.012 · Cited by 139 · cited 1×
“LOH in N1::Crelo/fl mice became evident when all animals developed corneal hyperplasia after 2–3 months (Figure 1C), as previously reported for mice with corneal Notch1 deletion (22).”
BackgroundDou, G., Wang, Y., Hu, X., Hou, L., Wang, C., Xu, J., Wang, Y., Liang, Y., Yao, L., Yang, A., et al. (2007) · The FASEB Journal · doi:10.1096/fj.07-9998com · Cited by 118
Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL
Jeannet, R., Mastio, J., Macias-Garcia, A., Oravecz, A., Ashworth, T., Geimer Le Lay, A.-S., Jost, B., Le Gras, S., Ghysdael, J., Gridley, T., et al. (2010) · Blood · doi:10.1182/blood-2010-05-286658 · Cited by 83 · cited 2×
“Jeannet R, et al. Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL [published online ahead of print September 9, 2010].”
BackgroundNotch2 is required for the proliferation of cardiac neural crest‐derived smooth muscle cells
Varadkar, P., Kraman, M., Despres, D., Ma, G., Lozier, J., & McCright, B. (2008) · Developmental Dynamics · doi:10.1002/dvdy.21502 · Cited by 74
Notch1 Signaling Influences V2 Interneuron and Motor Neuron Development in the Spinal Cord
Yang, X., Tomita, T., Wines-Samuelson, M., Beglopoulos, V., Tansey, M. G., Kopan, R., & Shen, J. (2006) · Developmental Neuroscience · doi:10.1159/000090757 · Cited by 71 · cited 1×
“7), with a floxed Notch1 allele (8) to perform an unbiased survey of cell types that will gain a growth advantage when Notch1 is lost.”
BackgroundSelf-citationRhodes, J. M., & Milton, J. D. (1997) · Humana Press eBooks · doi:10.1385/0896033961 · Cited by 60
New Genetic Tactics to Model Alveolar Rhabdomyosarcoma in the Mouse
Keller, C., & Capecchi, M. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0477 · Cited by 56 · cited 2×
“To circumvent this problem, most genetic approaches adopt transgenic or Cre-LoxP–based conditional loss-of-function strategies (30) to express or remove a gene of interest in most or all cells within a population.”
BackgroundMethodA CreER-Based Random Induction Strategy for Modeling Translocation-Associated Sarcomas in Mice
Haldar, M., Hedberg, M. L., Hockin, M. F., & Capecchi, M. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4127 · Cited by 43 · cited 1×
“Such strategy has been recently used to induce the sporadic expression of a SYT-SSX2 fusion gene in multiple tissues, resulting in exclusively synovial sarcoma-like tumors (31).”
A simple, robust hardware device for passive or active respiratory gating in MRI and MRS experiments
Garbow, J. R., Dugas, J. P., Song, S., & Conradi, M. S. (2004) · Concepts in Magnetic Resonance Part B · doi:10.1002/cmr.b.20010 · Cited by 28 · cited 1×
“tory-gating unit (44), and all images were collected during postexpiratory”
BackgroundSelf-citationLiu, Z., Obenauf, A. C., Speicher, M. R., & Kopan, R. (2009) · Genome Research · doi:10.1101/gr.093856.109 · Cited by 18 · cited 1×
“amount of N1::Cre fusion protein, is described previously (21, 20) and”
Self-citationLectins as Tools for the Purification of Liver Endothelial Cells
Gomez, D. E., & Thorgeirsson, U. P. (2003) · Humana Press eBooks · doi:10.1385/0-89603-396-1:319 · Cited by 3 · cited 2×
“org Volume 121 Number 2 February 2011 807 Percoll gradient centrifugation (25) and stained with PerCP-Cy5.”
BackgroundMethod
Cited by
Basic and Therapeutic Aspects of Angiogenesis
Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771
“Conversely, blockade of DLL4 or Notch1 in the adult causes vascular tumors and hemorrhage (Liu et al., 2011; Yan et al., 2010).”
Alzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424
Notch Signaling in Development, Tissue Homeostasis, and Disease
Siebel, C., & Lendahl, U. (2017) · Physiological Reviews · doi:10.1152/physrev.00005.2017 · Cited by 978
Endothelial Cell Heterogeneity
Aird, W. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006429 · Cited by 731
“A recent report showed a cell autonomous role for Notch1 in suppressing tumors of the endothelium (Liu et al. 2011).”
BackgroundVascular heterogeneity and specialization in development and disease
Potente, M., & Mäkinen, T. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.36 · Cited by 653
Metadata
- Authors
- Liu, Z., Turkoz, A., Jackson, E. N., Corbo, J. C., Engelbach, J. A., Garbow, J. R., Piwnica-Worms, D. R., & Kopan, R.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Kopan, Raphael
- Venue
- Journal of Clinical Investigation
- Published
- 2011-02-01
- Volume
- 121
- Issue
- 2
- Pages
- 800-808
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3026721
- OpenAlex
- W2145967409
- Cited by
- 119
- References
- 45
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 4 · 2021: 2 · 2020: 4 · 2019: 2 · 2018: 8 · 2017: 8 · 2016: 6 · 2015: 12 · 2014: 15 · 2013: 18 · 2012: 10
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Funders
- Alvin J. Siteman Cancer Center
- National Institutes of Health
- National Eye Institute (R01EY018826)
- National Cancer Institute (P30 CA 91842, U24CA083060, U24 CA83060, P50CA094056, P30CA091842)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK066408)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- Notch1, loss of heterozygosity, tumor suppressor function, vascular tumors, hemorrhage, Notch signaling, conditional alleles, drug safety, mouse model
- MeSH terms
- Animals, Hemorrhage, Humans, Magnetic Resonance Imaging, Recombinant Fusion Proteins, Signal Transduction, Survival Rate, Disease Progression, Vascular Neoplasms, Loss of Heterozygosity, Mice, Receptor, Notch1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.